首页 > 最新文献

Asia-Pacific journal of clinical oncology最新文献

英文 中文
Thoracic Cancer Exercise Services in Australia: A Point-Prevalence Survey.
IF 1.4 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-17 DOI: 10.1111/ajco.14157
Amy Bowman, Linda Denehy, Lara Edbrooke

Background: Cancer guidelines recommend pre- and rehabilitation; however, current research shows these services are not well integrated into clinical practice. To date, there has been no prospective audit of Australian lung cancer exercise services or the people accessing these services. The aim of this study was to describe the exercise pre- and rehabilitation services available to people with thoracic cancer and the characteristics of people with thoracic cancer attending these services in Australia.

Methods: Prospective, observational, multicenter, 5-day, point-prevalence study. Australian healthcare services likely to provide exercise services to people with thoracic cancer were contacted to participate. Conduct and reporting followed the CROSS guidelines.

Results: A total of 397 services were contacted, and 203 responded (51%). Overall, 67% (n = 137) accepted thoracic cancer referrals, and 107 (78%) completed the survey. Most exercise services were targeted at respiratory disease (58%, n = 60) compared with 31% cancer-specific (n = 33) and 5% lung cancer-specific (n = 5). A total of 73 patients with thoracic cancer attended programs across 41 sites (38%). Mean (SD) age was 68.5 (9.7) years. Overall, 4% of patients (n = 3) were culturally and linguistically diverse, and none identified as Aboriginal or Torres Strait Islander. A total of 19 outcomes were used in 51 combinations to assess participants (n = 70), and 12 exercise interventions were delivered in 45 combinations (n = 67).

Conclusions: One-third of responding exercise programs did not offer exercise services to people with thoracic cancer. Almost two-thirds of services that accept referrals did not have a thoracic cancer patient attend their service. High heterogeneity in outcome measures and exercise interventions was observed.

{"title":"Thoracic Cancer Exercise Services in Australia: A Point-Prevalence Survey.","authors":"Amy Bowman, Linda Denehy, Lara Edbrooke","doi":"10.1111/ajco.14157","DOIUrl":"https://doi.org/10.1111/ajco.14157","url":null,"abstract":"<p><strong>Background: </strong>Cancer guidelines recommend pre- and rehabilitation; however, current research shows these services are not well integrated into clinical practice. To date, there has been no prospective audit of Australian lung cancer exercise services or the people accessing these services. The aim of this study was to describe the exercise pre- and rehabilitation services available to people with thoracic cancer and the characteristics of people with thoracic cancer attending these services in Australia.</p><p><strong>Methods: </strong>Prospective, observational, multicenter, 5-day, point-prevalence study. Australian healthcare services likely to provide exercise services to people with thoracic cancer were contacted to participate. Conduct and reporting followed the CROSS guidelines.</p><p><strong>Results: </strong>A total of 397 services were contacted, and 203 responded (51%). Overall, 67% (n = 137) accepted thoracic cancer referrals, and 107 (78%) completed the survey. Most exercise services were targeted at respiratory disease (58%, n = 60) compared with 31% cancer-specific (n = 33) and 5% lung cancer-specific (n = 5). A total of 73 patients with thoracic cancer attended programs across 41 sites (38%). Mean (SD) age was 68.5 (9.7) years. Overall, 4% of patients (n = 3) were culturally and linguistically diverse, and none identified as Aboriginal or Torres Strait Islander. A total of 19 outcomes were used in 51 combinations to assess participants (n = 70), and 12 exercise interventions were delivered in 45 combinations (n = 67).</p><p><strong>Conclusions: </strong>One-third of responding exercise programs did not offer exercise services to people with thoracic cancer. Almost two-thirds of services that accept referrals did not have a thoracic cancer patient attend their service. High heterogeneity in outcome measures and exercise interventions was observed.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In Reply to Chen, et al.: Towards Systematic and Sustained Integration of Shared Decision Making in Oncology in the Asia-Pacific.
IF 1.4 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-17 DOI: 10.1111/ajco.14159
Warren Bacorro, Clarito Cairo, Kathleen Baldivia, Aida Bautista, Evelyn Dancel, Jocelyn Mariano, Gil Gonzalez, Teresa Sy Ortin, Rodel Canlas
{"title":"In Reply to Chen, et al.: Towards Systematic and Sustained Integration of Shared Decision Making in Oncology in the Asia-Pacific.","authors":"Warren Bacorro, Clarito Cairo, Kathleen Baldivia, Aida Bautista, Evelyn Dancel, Jocelyn Mariano, Gil Gonzalez, Teresa Sy Ortin, Rodel Canlas","doi":"10.1111/ajco.14159","DOIUrl":"https://doi.org/10.1111/ajco.14159","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pneumocystis jirovecii Pneumonia in Cancer Patients, a Lethal Yet Fully Preventable Disease: Insights From a Tertiary Cancer Center in East India.
IF 1.4 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-14 DOI: 10.1111/ajco.14156
S Chatterji, V Franchi, A J Konnakottu, P Das, S Mukherjee, S Bhattacharya, A Chatterjee

Background: Pneumocystis jirovecii pneumonia (PCP) is an unrecognized infection in non-HIV patients, particularly those with solid and hematologic malignancies. These patients experience higher mortality rates. This study aims to describe the incidence, initial characteristics, management, and outcomes of PCP at a tertiary cancer care center.

Methods: This retrospective observational study included all patients who underwent P. jirovecii PCR testing at our center from January 2019 to January 2022. PCP was diagnosed in PCR-positive patients. Data on demographics, treatment, and outcomes were extracted from medical records. The primary outcomes were ICU admission and 21-day mortality. Statistical analysis compared PCR-positive and PCR-negative patients, with a specific focus on lung cancer patients, and analyzed determinants of 21-day mortality in PCP patients.

Results: Of the 345 patients suspected of PCP, 54 (15.7%) were diagnosed with PCP. PCP patients were generally older. None of the PCP patients were on prophylaxis, compared to 14.8% of PCR-negative patients. In lung cancer patients, age and radiotherapy within the past year were significantly associated with a PCP diagnosis. The 21-day mortality rate among PCP patients was 35.4%. Independent risk factors for mortality included age and hematologic malignancy, while recent chemotherapy and higher neutrophil counts were associated with lower mortality.

Conclusion: PCP is associated with the highest mortality in patients with hematologic malignancies and lung cancer. The findings underscore the importance and efficacy of prophylaxis in at-risk groups and should raise awareness for the diagnosis of PCP in overlooked populations, such as older cancer patients and those undergoing radiotherapy.

{"title":"Pneumocystis jirovecii Pneumonia in Cancer Patients, a Lethal Yet Fully Preventable Disease: Insights From a Tertiary Cancer Center in East India.","authors":"S Chatterji, V Franchi, A J Konnakottu, P Das, S Mukherjee, S Bhattacharya, A Chatterjee","doi":"10.1111/ajco.14156","DOIUrl":"https://doi.org/10.1111/ajco.14156","url":null,"abstract":"<p><strong>Background: </strong>Pneumocystis jirovecii pneumonia (PCP) is an unrecognized infection in non-HIV patients, particularly those with solid and hematologic malignancies. These patients experience higher mortality rates. This study aims to describe the incidence, initial characteristics, management, and outcomes of PCP at a tertiary cancer care center.</p><p><strong>Methods: </strong>This retrospective observational study included all patients who underwent P. jirovecii PCR testing at our center from January 2019 to January 2022. PCP was diagnosed in PCR-positive patients. Data on demographics, treatment, and outcomes were extracted from medical records. The primary outcomes were ICU admission and 21-day mortality. Statistical analysis compared PCR-positive and PCR-negative patients, with a specific focus on lung cancer patients, and analyzed determinants of 21-day mortality in PCP patients.</p><p><strong>Results: </strong>Of the 345 patients suspected of PCP, 54 (15.7%) were diagnosed with PCP. PCP patients were generally older. None of the PCP patients were on prophylaxis, compared to 14.8% of PCR-negative patients. In lung cancer patients, age and radiotherapy within the past year were significantly associated with a PCP diagnosis. The 21-day mortality rate among PCP patients was 35.4%. Independent risk factors for mortality included age and hematologic malignancy, while recent chemotherapy and higher neutrophil counts were associated with lower mortality.</p><p><strong>Conclusion: </strong>PCP is associated with the highest mortality in patients with hematologic malignancies and lung cancer. The findings underscore the importance and efficacy of prophylaxis in at-risk groups and should raise awareness for the diagnosis of PCP in overlooked populations, such as older cancer patients and those undergoing radiotherapy.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143424914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implementing Shared Decision-Making in Oncology: Lessons From Taiwan's Experience for the Philippine Health-Care System.
IF 1.4 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-13 DOI: 10.1111/ajco.14161
Li-Hua Chen, Lien-Chung Wei, Hsien-Jane Chiu
{"title":"Implementing Shared Decision-Making in Oncology: Lessons From Taiwan's Experience for the Philippine Health-Care System.","authors":"Li-Hua Chen, Lien-Chung Wei, Hsien-Jane Chiu","doi":"10.1111/ajco.14161","DOIUrl":"https://doi.org/10.1111/ajco.14161","url":null,"abstract":"","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management Experience of T1 Glottic Cancer Treated by CO2 Laser Surgery: A Cohort of 173 Patients.
IF 1.4 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-09 DOI: 10.1111/ajco.14155
Changjiang Li, Jian Chen, Peijie He, Lei Cheng, Haitao Wu

It was aimed to explore an alternative solution to manage T1 glottic cancer patients. One hundred seventy-three patients were enrolled. Seventy-eight cases were treated with type I and proved to be microinvasion cancer. Of them, 21 willingly selected followed up and 57 were further undergone type II. Ninety-five underwent type III and confirmed to be superficial invasion cancer in which Reinke's space was invaded. Five(23.8%), four(7.0%) and nine (9.5%)cases separately relapsed in type I, II and III. No significant difference was observed (p>0.05). 5/60, 5/11 and 8/102 patients respectively replaced in negative, positive and uncertain margin groups. There were remarkable differences among them (p<0.05). The recurrence rate is still low for patients with early glottic cancer undergone vocal cord resection using CO2 laser, and the appropriate surgical method should be selected for a diverse range of glottic cancer to avoid overtreatment. Patients with positive incisal margins have a relatively high recurrence rate and should take this situation seriously.

{"title":"Management Experience of T1 Glottic Cancer Treated by CO<sub>2</sub> Laser Surgery: A Cohort of 173 Patients.","authors":"Changjiang Li, Jian Chen, Peijie He, Lei Cheng, Haitao Wu","doi":"10.1111/ajco.14155","DOIUrl":"https://doi.org/10.1111/ajco.14155","url":null,"abstract":"<p><p>It was aimed to explore an alternative solution to manage T1 glottic cancer patients. One hundred seventy-three patients were enrolled. Seventy-eight cases were treated with type I and proved to be microinvasion cancer. Of them, 21 willingly selected followed up and 57 were further undergone type II. Ninety-five underwent type III and confirmed to be superficial invasion cancer in which Reinke's space was invaded. Five(23.8%), four(7.0%) and nine (9.5%)cases separately relapsed in type I, II and III. No significant difference was observed (p>0.05). 5/60, 5/11 and 8/102 patients respectively replaced in negative, positive and uncertain margin groups. There were remarkable differences among them (p<0.05). The recurrence rate is still low for patients with early glottic cancer undergone vocal cord resection using CO<sub>2</sub> laser, and the appropriate surgical method should be selected for a diverse range of glottic cancer to avoid overtreatment. Patients with positive incisal margins have a relatively high recurrence rate and should take this situation seriously.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143381471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Smoking Cessation Practices in Australian Oncology Settings: A Cross-Sectional Study of Who, How, and When.
IF 1.4 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-05 DOI: 10.1111/ajco.14148
Alison Luk Young, Melissa McEnallay, Fiona Day, Shalini K Vinod, Emily Stone, Sarah Morris, Elena Stefanovska, Bianca Devitt, Po Yee Yip, Craig Kukard, Abhijit Pal, Vaibhav Thawal, Gavin Wright, Alison Hofman, Heena Sareen, James McLennan, Shuet Oi Wong, Cassandra Rubio, Jennifer Liu, Alexandra Smith, Dimity Betts, Jane Mack, Jennifer Donnelly, Christine Paul

Purpose: Patients who smoke tobacco during and after a cancer diagnosis have poorer health outcomes. Oncology healthcare providers (HCPs) are crucial to providing smoking cessation support. The study examined the characteristics associated with differences in HCPs' smoking cessation practices.

Methods: As part of the Care to Quit trial, a cross-sectional survey exploring smoking cessation practices was completed by HCPs across nine cancer centers in New South Wales and Victoria, Australia.

Results: One hundred and seventy-seven HCPs completed the survey. Over half of the HCP respondents reported asking patients their smoking status, but fewer than half advised patients about the benefits of quitting, referred patients to behavioral support such as Quitline, or offered pharmacotherapy medication. All components of the "3A's" model (Ask, Advise, Act) were more likely to be completed by doctors compared to registered nurses (OR: 7.86, 95% CI: 3.64, 16.95, p<0.001), by those with more years of practice (OR: 0.26, 95% CI: 0.07-0.93, p = 0.039), and those who had received smoking cessation training (OR: 3.91, 95% CI: 1.80, 8.48, p = 0.001). Multivariate analyses also identified differences in the amount of cancer-specific advice provided between occupation type (p<0.001) and years of practice (p = 0.021).

Conclusion: The need for smoking cessation care training in oncology continues to be apparent. Training in prescribing pharmacotherapies (for doctors) or supporting the use of pharmacotherapies (for nurses) is a particular "gap." Differences between the roles and engagement of doctors and nurses in relation to smoking cessation care should be carefully considered when developing site-specific models of cessation care and providing training.

{"title":"Smoking Cessation Practices in Australian Oncology Settings: A Cross-Sectional Study of Who, How, and When.","authors":"Alison Luk Young, Melissa McEnallay, Fiona Day, Shalini K Vinod, Emily Stone, Sarah Morris, Elena Stefanovska, Bianca Devitt, Po Yee Yip, Craig Kukard, Abhijit Pal, Vaibhav Thawal, Gavin Wright, Alison Hofman, Heena Sareen, James McLennan, Shuet Oi Wong, Cassandra Rubio, Jennifer Liu, Alexandra Smith, Dimity Betts, Jane Mack, Jennifer Donnelly, Christine Paul","doi":"10.1111/ajco.14148","DOIUrl":"https://doi.org/10.1111/ajco.14148","url":null,"abstract":"<p><strong>Purpose: </strong>Patients who smoke tobacco during and after a cancer diagnosis have poorer health outcomes. Oncology healthcare providers (HCPs) are crucial to providing smoking cessation support. The study examined the characteristics associated with differences in HCPs' smoking cessation practices.</p><p><strong>Methods: </strong>As part of the Care to Quit trial, a cross-sectional survey exploring smoking cessation practices was completed by HCPs across nine cancer centers in New South Wales and Victoria, Australia.</p><p><strong>Results: </strong>One hundred and seventy-seven HCPs completed the survey. Over half of the HCP respondents reported asking patients their smoking status, but fewer than half advised patients about the benefits of quitting, referred patients to behavioral support such as Quitline, or offered pharmacotherapy medication. All components of the \"3A's\" model (Ask, Advise, Act) were more likely to be completed by doctors compared to registered nurses (OR: 7.86, 95% CI: 3.64, 16.95, p<0.001), by those with more years of practice (OR: 0.26, 95% CI: 0.07-0.93, p = 0.039), and those who had received smoking cessation training (OR: 3.91, 95% CI: 1.80, 8.48, p = 0.001). Multivariate analyses also identified differences in the amount of cancer-specific advice provided between occupation type (p<0.001) and years of practice (p = 0.021).</p><p><strong>Conclusion: </strong>The need for smoking cessation care training in oncology continues to be apparent. Training in prescribing pharmacotherapies (for doctors) or supporting the use of pharmacotherapies (for nurses) is a particular \"gap.\" Differences between the roles and engagement of doctors and nurses in relation to smoking cessation care should be carefully considered when developing site-specific models of cessation care and providing training.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating the Effect of Oral Famotidine in Preventing Hypersensitivity Reactions in Individuals Receiving Platinum-Based Agents or Taxanes. 评估口服法莫替丁对预防接受铂类药物或紫杉类药物治疗者过敏反应的影响
IF 1.4 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-04 DOI: 10.1111/ajco.14154
Faraz Tohidifar, Mohammad Mohammadzadeh, Elnaz Shaseb, Samineh Beheshtirouy, Parvin Sarbakhsh, Saba Ghaffary

Introduction: Hypersensitivity reactions (HSRs), an unpredictable and sometimes harmful reaction, may hamper the effectiveness of chemotherapy and lead to the need for drug switching. The recall of ranitidine from the drug market due to the N-nitrosodimethylamine production necessitates the identification of a proper alternative for the prevention of HSRs. Our study aimed to evaluate the efficacy of oral famotidine in the prevention of HSRs in patients who received chemotherapy agents, particularly platinum-based and taxanes.

Methods: A total of 426 patients who were treated with platinum-based agents or taxanes as part of their regimen were divided into two groups. The famotidine group, including 213 patients, received the standard premedication along with an oral dose of 40 mg famotidine the night before and 1 h prior to the chemotherapy session. The control group, also including 213 patients, received only the standard premedication without famotidine.

Results: Based on the results of this study, six patients in the control group experienced HSRs with a range of varying severities. No HSRs were observed by any of the patients in the famotidine group (p-value = 0.022).

Conclusion: Administration of oral famotidine is beneficial in preventing chemotherapy-induced HSRs.

Clinical trial registration: It was also registered with the Iran Clinical Trial Centre under code IRCT20160310026998N13.

{"title":"Evaluating the Effect of Oral Famotidine in Preventing Hypersensitivity Reactions in Individuals Receiving Platinum-Based Agents or Taxanes.","authors":"Faraz Tohidifar, Mohammad Mohammadzadeh, Elnaz Shaseb, Samineh Beheshtirouy, Parvin Sarbakhsh, Saba Ghaffary","doi":"10.1111/ajco.14154","DOIUrl":"https://doi.org/10.1111/ajco.14154","url":null,"abstract":"<p><strong>Introduction: </strong>Hypersensitivity reactions (HSRs), an unpredictable and sometimes harmful reaction, may hamper the effectiveness of chemotherapy and lead to the need for drug switching. The recall of ranitidine from the drug market due to the N-nitrosodimethylamine production necessitates the identification of a proper alternative for the prevention of HSRs. Our study aimed to evaluate the efficacy of oral famotidine in the prevention of HSRs in patients who received chemotherapy agents, particularly platinum-based and taxanes.</p><p><strong>Methods: </strong>A total of 426 patients who were treated with platinum-based agents or taxanes as part of their regimen were divided into two groups. The famotidine group, including 213 patients, received the standard premedication along with an oral dose of 40 mg famotidine the night before and 1 h prior to the chemotherapy session. The control group, also including 213 patients, received only the standard premedication without famotidine.</p><p><strong>Results: </strong>Based on the results of this study, six patients in the control group experienced HSRs with a range of varying severities. No HSRs were observed by any of the patients in the famotidine group (p-value = 0.022).</p><p><strong>Conclusion: </strong>Administration of oral famotidine is beneficial in preventing chemotherapy-induced HSRs.</p><p><strong>Clinical trial registration: </strong>It was also registered with the Iran Clinical Trial Centre under code IRCT20160310026998N13.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comparison of Australian Oncology Clinicians' Smoking Cessation Care Practices for People Who Currently Smoke Versus Those Who Report Recently Stopping Smoking.
IF 1.4 4区 医学 Q4 ONCOLOGY Pub Date : 2025-02-01 DOI: 10.1111/ajco.14153
Alison Luk Young, Melissa McEnallay, Fiona Day, Shalini K Vinod, Emily Stone, Sarah Morris, Elena Stefanovska, Bianca Devitt, Po Yee Yip, Craig Kukard, Abhijit Pal, Vaibhav Thawal, Gavin Wright, Alison Hofman, Heena Sareen, James McLennan, Shuet Oi Wong, Cassandra Rubio, Jennifer Liu, Alexandra Smith, Dimity Betts, Jane Mack, Jennifer Donnelly, Daniel Barker, Christine Paul

Aim: Smoking is a chronic relapsing condition that is under-reported in oncology settings. People who report current smoking (CS) and those who report recently quitting smoking (RQ) should receive cessation support when they are diagnosed with cancer. The study aimed to identify whether differences exist in the smoking cessation support given to CS and RQ in oncology and what advice is given regarding the benefits of cessation.

Method: A survey exploring smoking cessation practices was completed by oncology clinicians (medical, nursing, and allied health) at nine cancer centers in Australia. Data were analyzed using mixed-effects ordinal regression modeling.

Results: Across the 177 clinicians completing the survey, the reported provision of smoking cessation care was significantly higher for CS than for RQ in relation to asking about smoking status (odds ratio [OR] 3.03, p = 0.001), advice on the benefits of quitting (OR 2.86, p = 0.001), and advice to call the Quitline (OR 5.08, p < 0.001). Exploratory analyses indicated doctors and nurse specialists were four times more likely to report referring CS to a Quitline compared to RQ (OR 4.38, p = 0.001; OR 4.29, 95%, p = 0.005, respectively). The cessation benefits that clinicians most often cited to their patients was that quitting "can reduce the chance of developing treatment complications and side effects".

Conclusion: The relative lack of smoking cessation care provided to RQ in oncology suggests that the high risk of smoking relapse is not well-recognized. Greater awareness and training are needed regarding advising RQ about the survival-specific benefits of continuing to not smoke, offering referrals, and offering follow-up support.

{"title":"A Comparison of Australian Oncology Clinicians' Smoking Cessation Care Practices for People Who Currently Smoke Versus Those Who Report Recently Stopping Smoking.","authors":"Alison Luk Young, Melissa McEnallay, Fiona Day, Shalini K Vinod, Emily Stone, Sarah Morris, Elena Stefanovska, Bianca Devitt, Po Yee Yip, Craig Kukard, Abhijit Pal, Vaibhav Thawal, Gavin Wright, Alison Hofman, Heena Sareen, James McLennan, Shuet Oi Wong, Cassandra Rubio, Jennifer Liu, Alexandra Smith, Dimity Betts, Jane Mack, Jennifer Donnelly, Daniel Barker, Christine Paul","doi":"10.1111/ajco.14153","DOIUrl":"https://doi.org/10.1111/ajco.14153","url":null,"abstract":"<p><strong>Aim: </strong>Smoking is a chronic relapsing condition that is under-reported in oncology settings. People who report current smoking (CS) and those who report recently quitting smoking (RQ) should receive cessation support when they are diagnosed with cancer. The study aimed to identify whether differences exist in the smoking cessation support given to CS and RQ in oncology and what advice is given regarding the benefits of cessation.</p><p><strong>Method: </strong>A survey exploring smoking cessation practices was completed by oncology clinicians (medical, nursing, and allied health) at nine cancer centers in Australia. Data were analyzed using mixed-effects ordinal regression modeling.</p><p><strong>Results: </strong>Across the 177 clinicians completing the survey, the reported provision of smoking cessation care was significantly higher for CS than for RQ in relation to asking about smoking status (odds ratio [OR] 3.03, p = 0.001), advice on the benefits of quitting (OR 2.86, p = 0.001), and advice to call the Quitline (OR 5.08, p < 0.001). Exploratory analyses indicated doctors and nurse specialists were four times more likely to report referring CS to a Quitline compared to RQ (OR 4.38, p = 0.001; OR 4.29, 95%, p = 0.005, respectively). The cessation benefits that clinicians most often cited to their patients was that quitting \"can reduce the chance of developing treatment complications and side effects\".</p><p><strong>Conclusion: </strong>The relative lack of smoking cessation care provided to RQ in oncology suggests that the high risk of smoking relapse is not well-recognized. Greater awareness and training are needed regarding advising RQ about the survival-specific benefits of continuing to not smoke, offering referrals, and offering follow-up support.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143073557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Four Weeks of Moderately Hypofractionated Chemoradiation for Unresectable, Stage 3 Non-Small Cell Lung Cancer: A Systematic Review.
IF 1.4 4区 医学 Q4 ONCOLOGY Pub Date : 2025-01-29 DOI: 10.1111/ajco.14152
Joanna Jane Ludbrook, Mahesh Kumar, Yu Yang Soon, Angela Smith, Girish Mallesara, Eric Hau, Fiona Hegi-Johnson, Shalini Vinod

Shortening treatment time with moderately hypofractionated radiotherapy benefits patients by reducing inconvenience and costs, but its use in the definitive treatment of unresectable Stage 3 non-small cell lung cancer is controversial due to lack of level one evidence and toxicity concerns. Pivotal systemic therapy trials utilize conventionally fractionated chemoradiation at 2 Gy per fraction given over 6 weeks. In practice, 4 weeks of chemoradiation at 2.75 Gy per fraction is sometimes employed to reduce the treatment burden for selected patients, especially those who are older or have comorbidities. It is uncertain if the two fractionation regimens are similar in biologically effectiveness, especially with varying systemic therapy. This systematic review aimed to collate the survival and toxicity outcomes for 4 weeks of moderately hypofractionated chemoradiation, using > 50 -60 Gy in 20 fractions. Eight studies met the eligibility criteria; seven studies were from a database search of MEDLINE, EMBASE, Cochrane Library, and Web of Science and one study was added later. Two studies were prospective randomized trials and six were retrospective cohort studies. No study included immunotherapy. The historical evidence has been limited, but emerging data is promising, especially when compared to outcomes of standard chemoradiation. Thus, further investigation of this strategy is justified.

{"title":"Efficacy and Safety of Four Weeks of Moderately Hypofractionated Chemoradiation for Unresectable, Stage 3 Non-Small Cell Lung Cancer: A Systematic Review.","authors":"Joanna Jane Ludbrook, Mahesh Kumar, Yu Yang Soon, Angela Smith, Girish Mallesara, Eric Hau, Fiona Hegi-Johnson, Shalini Vinod","doi":"10.1111/ajco.14152","DOIUrl":"https://doi.org/10.1111/ajco.14152","url":null,"abstract":"<p><p>Shortening treatment time with moderately hypofractionated radiotherapy benefits patients by reducing inconvenience and costs, but its use in the definitive treatment of unresectable Stage 3 non-small cell lung cancer is controversial due to lack of level one evidence and toxicity concerns. Pivotal systemic therapy trials utilize conventionally fractionated chemoradiation at 2 Gy per fraction given over 6 weeks. In practice, 4 weeks of chemoradiation at 2.75 Gy per fraction is sometimes employed to reduce the treatment burden for selected patients, especially those who are older or have comorbidities. It is uncertain if the two fractionation regimens are similar in biologically effectiveness, especially with varying systemic therapy. This systematic review aimed to collate the survival and toxicity outcomes for 4 weeks of moderately hypofractionated chemoradiation, using > 50 -60 Gy in 20 fractions. Eight studies met the eligibility criteria; seven studies were from a database search of MEDLINE, EMBASE, Cochrane Library, and Web of Science and one study was added later. Two studies were prospective randomized trials and six were retrospective cohort studies. No study included immunotherapy. The historical evidence has been limited, but emerging data is promising, especially when compared to outcomes of standard chemoradiation. Thus, further investigation of this strategy is justified.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143063418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients' Perceptions of the Efficacy, Safety, and Quality of the Evidence of Medicinal Cannabis: A Survey of Australian Cancer Patients. 患者对药用大麻疗效、安全性和证据质量的看法:澳大利亚癌症患者的调查。
IF 1.4 4区 医学 Q4 ONCOLOGY Pub Date : 2025-01-19 DOI: 10.1111/ajco.14149
Elizabeth A Fradgley, Ben Britton Britton, Jennifer H Martin, Catherine Lucas, Melissa A Carlson, Paula Bridge, Sarah Morris, Gareth Watts, James Lynam, Joseph S Taylor

Introduction: Despite the increased demand for medical cannabis (MC), MASCC guidelines state that there is insufficient evidence of its efficacy and safety. Although research has explored medical professionals' perceptions of MC, there is to our knowledge minimal research exploring patients' perceptions, particularly in an Australian cancer setting.

Methods: A survey of Australian cancer patients attending oncology outpatient clinics was performed. Patients were ≥ 18 years and had a confirmed diagnosis of cancer (solid or hematological).

Results: A total of 413 patients were approached between April 2019 and March 2020 out of which 82% (350) consented to participate. A total of 19% (67/350) were using MC. Despite being used for symptom control, such as pain (61%), and, in some cases for perceived anticancer activity (12% to cure, and 16% to slow the cancer), only a minority of users believed that the evidence was of high quality for these indications (28% for physical benefits and 29% for anticancer activity). Nonusers were even more skeptical of the evidence for these indications (17% and 11%, respectively). Only a minority of patients (31% of users and 8% of nonusers) accessed information on MC from clinicians. Most instead relied on resources such as TV, friends, family, social media, and websites.

Conclusion: This study demonstrates current real-world cancer patients' perceptions on the evidence for MC, the sources of information used to shape their health beliefs, and compares users to nonusers. The results highlight the need for treating teams to combat potential misinformation that patients may be accessing about MC and provide information on treatments with stronger evidence.

导言:尽管对医用大麻(MC)的需求有所增加,但MASCC指南指出,没有足够的证据证明其有效性和安全性。虽然有研究探讨了医学专业人员对MC的看法,但据我们所知,探讨患者看法的研究很少,特别是在澳大利亚的癌症环境中。方法:对在肿瘤门诊就诊的澳大利亚癌症患者进行调查。患者年龄≥18岁,确诊为癌症(实体或血液学)。结果:在2019年4月至2020年3月期间,共接触了413名患者,其中82%(350)同意参与。总共有19%(67/350)的患者使用MC。尽管MC用于症状控制,如疼痛(61%),在某些情况下用于感知抗癌活性(12%用于治愈,16%用于减缓癌症),但只有少数用户认为这些适应症的证据质量高(28%用于身体益处,29%用于抗癌活性)。非使用者对这些适应症的证据更加怀疑(分别为17%和11%)。只有少数患者(31%的使用者和8%的非使用者)从临床医生那里获得了关于MC的信息。大多数人转而依赖电视、朋友、家人、社交媒体和网站等资源。结论:本研究展示了当前现实世界癌症患者对MC证据的看法,用于塑造其健康信念的信息来源,并比较了使用者和非使用者。研究结果强调,治疗团队需要打击患者可能获得的关于MC的潜在错误信息,并提供有更有力证据的治疗信息。
{"title":"Patients' Perceptions of the Efficacy, Safety, and Quality of the Evidence of Medicinal Cannabis: A Survey of Australian Cancer Patients.","authors":"Elizabeth A Fradgley, Ben Britton Britton, Jennifer H Martin, Catherine Lucas, Melissa A Carlson, Paula Bridge, Sarah Morris, Gareth Watts, James Lynam, Joseph S Taylor","doi":"10.1111/ajco.14149","DOIUrl":"https://doi.org/10.1111/ajco.14149","url":null,"abstract":"<p><strong>Introduction: </strong>Despite the increased demand for medical cannabis (MC), MASCC guidelines state that there is insufficient evidence of its efficacy and safety. Although research has explored medical professionals' perceptions of MC, there is to our knowledge minimal research exploring patients' perceptions, particularly in an Australian cancer setting.</p><p><strong>Methods: </strong>A survey of Australian cancer patients attending oncology outpatient clinics was performed. Patients were ≥ 18 years and had a confirmed diagnosis of cancer (solid or hematological).</p><p><strong>Results: </strong>A total of 413 patients were approached between April 2019 and March 2020 out of which 82% (350) consented to participate. A total of 19% (67/350) were using MC. Despite being used for symptom control, such as pain (61%), and, in some cases for perceived anticancer activity (12% to cure, and 16% to slow the cancer), only a minority of users believed that the evidence was of high quality for these indications (28% for physical benefits and 29% for anticancer activity). Nonusers were even more skeptical of the evidence for these indications (17% and 11%, respectively). Only a minority of patients (31% of users and 8% of nonusers) accessed information on MC from clinicians. Most instead relied on resources such as TV, friends, family, social media, and websites.</p><p><strong>Conclusion: </strong>This study demonstrates current real-world cancer patients' perceptions on the evidence for MC, the sources of information used to shape their health beliefs, and compares users to nonusers. The results highlight the need for treating teams to combat potential misinformation that patients may be accessing about MC and provide information on treatments with stronger evidence.</p>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Asia-Pacific journal of clinical oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1